
rofecoxib (Vioxx) might have to think again. The risks of the drug, which...studies suggest it might pose similar, though less severe, risks to the heart. Other related drugs, such as ibuprofen (Advil and generic) and ...

A generic drug called meloxicam is also available. It isn't a COX-2 inhibitior, but has some of the same benefits as the COX-2 inhibitors. For ...to send out any alarms. Q: What's the lesson from the Vioxx episode? ...

its Vioxx cases has eliminated a huge legal overhang," said Levenson...( Charts , Fortune 500 ), is still saddled with the some of the same problems plaguing the rest of Big Pharma: pressure from generic drugmakers. ...

into what should have been known about the risks of rofecoxib," they concluded, using the generic term for Vioxx. "If we are to detect harms early and protect the public's health, while ensuring the availability of...

But Vioxx isn't the only problem for Merck The company has also had to deal with patent expirations on potent blockbusters like Zocor, which peaked at more than $5 billion in annual sales before generic pressure...

were published, in medical journals, boosting Vioxx's profile in the crowded painkiller market. Vioxx, whose generic name is rofecoxib, went on the market in 1999. It became a "blockbuster," with $2.3 billion in...

account it appears, however, that generic versions of the powerful anti-acne medication will continue to be available

much the same as other anti-inflammatory painkillers , which sold for a fraction of the cost, but Vioxx (the generic name is rofecoxib) was designed to be less irritating to people's stomachs than older drugs in...

cheaper, generic statins. However, they noted that Lipitor still enjoys a favorable reimbursement listing with Medicare, recipients of which re...Celebrex belongs to the same class of drugs as Merck's Vioxx, which ...

its best-selling products start to face competition from generic medicines. The drug belongs to the same group of treatments as Merck & Co.¡¯s Vioxx, which was pulled from the market in 2004 after research...